The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

While the company is prioritizing RJVA-001 and a lead program in obesity, it's pausing some R&D efforts and laying off 17 percent of its workforce.

Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time curative therapies, today announced new ...

With permission from a data safety monitoring committee, the firm will begin treating a second cohort with AMT-162 in the EPISOD1 trial in early 2025.

ReiThera is proud to announce a new partnership with SillaJen through a comprehensive Master Service Agreement (MSA), which establishes ReiThera as the manufacturing partner for SillaJen’s innovative ...

The partners will adapt Eukarÿs' C3P3 engineered enzyme tech to work with adeno-associated virus vectors to boost biomanufacturing yields.

Genethon & Eukarÿs enter strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of gene therapies: Evry, France Friday, January 24, 2025, ...

The global gene transfer technologies market, valued at US$3.63 billion in 2023, is forecasted to grow at a robust CAGR of ...

Viralgen and Axovia Therapeutics are set to form a partnership to progress the development and manufacturing of an ...

Press release Genethon and Eukarÿs announce a strategic partnership to develop a breakthrough technology to reduce the ...

Gene editing technique developed in Switzerland shows promise in curing Stargardt disease, a rare genetic eye disease causing ...

New Vericheck ddPCR Empty-Full Capsid Kits for AAV Serotypes 2 and 8 Provide Precise Measurement of Viral Titer and Capsid ...